Cargando…

Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study

INTRODUCTION: Blood coagulation constituents might exert immunomodulatory functions in the CNS and may trigger neuroinflammation and demyelination. We evaluated whether particular single-nucleotide polymorphisms (SNPs), thought to be involved in fibrinogen-mediated hemostatic pathways, are overrepre...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbadessa, Gianmarco, Miele, Giuseppina, Di Pietro, Andrea, Sparaco, Maddalena, Palladino, Raffaele, Armetta, Ignazio, D’Elia, Giovanna, Trojsi, Francesca, Signoriello, Elisabetta, Lus, Giacomo, Lavorgna, Luigi, Bonavita, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918146/
https://www.ncbi.nlm.nih.gov/pubmed/34561786
http://dx.doi.org/10.1007/s10072-021-05608-1
_version_ 1784668672216793088
author Abbadessa, Gianmarco
Miele, Giuseppina
Di Pietro, Andrea
Sparaco, Maddalena
Palladino, Raffaele
Armetta, Ignazio
D’Elia, Giovanna
Trojsi, Francesca
Signoriello, Elisabetta
Lus, Giacomo
Lavorgna, Luigi
Bonavita, Simona
author_facet Abbadessa, Gianmarco
Miele, Giuseppina
Di Pietro, Andrea
Sparaco, Maddalena
Palladino, Raffaele
Armetta, Ignazio
D’Elia, Giovanna
Trojsi, Francesca
Signoriello, Elisabetta
Lus, Giacomo
Lavorgna, Luigi
Bonavita, Simona
author_sort Abbadessa, Gianmarco
collection PubMed
description INTRODUCTION: Blood coagulation constituents might exert immunomodulatory functions in the CNS and may trigger neuroinflammation and demyelination. We evaluated whether particular single-nucleotide polymorphisms (SNPs), thought to be involved in fibrinogen-mediated hemostatic pathways, are overrepresented in patients with MS compared with controls. METHODS: The case–control study consisted of 119 MS patients recruited consecutively at our clinic, and 68 healthy controls. Afterwards, we created a cumulative genetic risk score (CGRS) which included the 5 selected hemostatic risk alleles (Beta-Fibrinogen 455G/A, Glycoprotein IIIa P1A2, Factor V Leiden, Factor V H2R, and Prothrombin 20210G/A). Multivariate ordinal logistic regression and multivariate multinomial logistic regression were applied to evaluate the effect of CGRS on MS susceptibility. RESULTS: The FGB 455 G/A and Factor V H1299R variants might be associated with MS status, in the recessive and dominant model, respectively. A cumulative association of the five SNPs investigated with the disease was observed. DISCUSSION: We found that MS patients carried more pro-hemostatic variants than healthy controls. An increasing number of unfavorable alleles might increase the likelihood of being in the MS group, in the cumulative analysis. Our findings encourage to evaluating these variants in a larger population-based cohort. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10072-021-05608-1.
format Online
Article
Text
id pubmed-8918146
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-89181462022-03-17 Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study Abbadessa, Gianmarco Miele, Giuseppina Di Pietro, Andrea Sparaco, Maddalena Palladino, Raffaele Armetta, Ignazio D’Elia, Giovanna Trojsi, Francesca Signoriello, Elisabetta Lus, Giacomo Lavorgna, Luigi Bonavita, Simona Neurol Sci Original Article INTRODUCTION: Blood coagulation constituents might exert immunomodulatory functions in the CNS and may trigger neuroinflammation and demyelination. We evaluated whether particular single-nucleotide polymorphisms (SNPs), thought to be involved in fibrinogen-mediated hemostatic pathways, are overrepresented in patients with MS compared with controls. METHODS: The case–control study consisted of 119 MS patients recruited consecutively at our clinic, and 68 healthy controls. Afterwards, we created a cumulative genetic risk score (CGRS) which included the 5 selected hemostatic risk alleles (Beta-Fibrinogen 455G/A, Glycoprotein IIIa P1A2, Factor V Leiden, Factor V H2R, and Prothrombin 20210G/A). Multivariate ordinal logistic regression and multivariate multinomial logistic regression were applied to evaluate the effect of CGRS on MS susceptibility. RESULTS: The FGB 455 G/A and Factor V H1299R variants might be associated with MS status, in the recessive and dominant model, respectively. A cumulative association of the five SNPs investigated with the disease was observed. DISCUSSION: We found that MS patients carried more pro-hemostatic variants than healthy controls. An increasing number of unfavorable alleles might increase the likelihood of being in the MS group, in the cumulative analysis. Our findings encourage to evaluating these variants in a larger population-based cohort. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10072-021-05608-1. Springer International Publishing 2021-09-24 2022 /pmc/articles/PMC8918146/ /pubmed/34561786 http://dx.doi.org/10.1007/s10072-021-05608-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Abbadessa, Gianmarco
Miele, Giuseppina
Di Pietro, Andrea
Sparaco, Maddalena
Palladino, Raffaele
Armetta, Ignazio
D’Elia, Giovanna
Trojsi, Francesca
Signoriello, Elisabetta
Lus, Giacomo
Lavorgna, Luigi
Bonavita, Simona
Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study
title Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study
title_full Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study
title_fullStr Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study
title_full_unstemmed Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study
title_short Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study
title_sort multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918146/
https://www.ncbi.nlm.nih.gov/pubmed/34561786
http://dx.doi.org/10.1007/s10072-021-05608-1
work_keys_str_mv AT abbadessagianmarco multiplesclerosisandgeneticpolymorphismsinfibrinogenmediatedhemostaticpathwaysacasecontrolstudy
AT mielegiuseppina multiplesclerosisandgeneticpolymorphismsinfibrinogenmediatedhemostaticpathwaysacasecontrolstudy
AT dipietroandrea multiplesclerosisandgeneticpolymorphismsinfibrinogenmediatedhemostaticpathwaysacasecontrolstudy
AT sparacomaddalena multiplesclerosisandgeneticpolymorphismsinfibrinogenmediatedhemostaticpathwaysacasecontrolstudy
AT palladinoraffaele multiplesclerosisandgeneticpolymorphismsinfibrinogenmediatedhemostaticpathwaysacasecontrolstudy
AT armettaignazio multiplesclerosisandgeneticpolymorphismsinfibrinogenmediatedhemostaticpathwaysacasecontrolstudy
AT deliagiovanna multiplesclerosisandgeneticpolymorphismsinfibrinogenmediatedhemostaticpathwaysacasecontrolstudy
AT trojsifrancesca multiplesclerosisandgeneticpolymorphismsinfibrinogenmediatedhemostaticpathwaysacasecontrolstudy
AT signorielloelisabetta multiplesclerosisandgeneticpolymorphismsinfibrinogenmediatedhemostaticpathwaysacasecontrolstudy
AT lusgiacomo multiplesclerosisandgeneticpolymorphismsinfibrinogenmediatedhemostaticpathwaysacasecontrolstudy
AT lavorgnaluigi multiplesclerosisandgeneticpolymorphismsinfibrinogenmediatedhemostaticpathwaysacasecontrolstudy
AT bonavitasimona multiplesclerosisandgeneticpolymorphismsinfibrinogenmediatedhemostaticpathwaysacasecontrolstudy